TAS266
TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
(VHH-VHH-hFc)-dimer
Human
TAS266 is up to 1000-fold more potent than cross-linked DR5 antibody or TRAIL at inducing cell death in cancer cell lines via DR5 activation, with faster downstream caspase activation kinetics[1].
TAS266 potently induces death in human tumor cell lines, with potency ≥1000-fold greater than cross-linked DR5 antibody LBY135 or TRAIL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TAS266 (single dose; weekly) induces tumor regression in a variety of tumor xenograft models, and its antitumor activity with weekly administration is superior to that of DR5 agonist antibodies in pancreatic cancer and colon cancer xenograft models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:specific strain not specified[2]
-
Dosage:200 mg/kg
-
Administration:twice weekly
-
Result:Showed no clinical or histopathologic evidence of target organ toxicity, including negative caspase immunohistochemistry of liver tissue.
Maintained bioactivity despite presence of preexisting or treatment-emergent TAS266-binding IgG antibodies in some animals.
-
Animal Model:specific strain not specified (immunocompromised)[2]
-
Dosage:Single dose; weekly dose
-
Administration:single dose; weekly
-
Result:Elicited tumor regressions in multiple human tumor xenograft models.
Exhibited superior anti-tumor activity compared with a DR5 agonist antibody in patient-derived pancreatic and colon xenograft models.
TNFRSF10B/TRAILR2/CD262
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TAS266 Related Classifications
HY-P992473 Related Classifications
Powered by Bioz